logo

TXG

10x Genomics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 4
consensus rating "Strong Buy"
Downward Gap
Price Hits New Low
Price Hits 52-week low
Revenue Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About TXG

10x Genomics, Inc.

A life sciences leader that develops instruments, consumables and software for analyzing biological systems complexity of biology

Life Science Tools and Services
07/02/2012
09/12/2019
NASDAQ Stock Exchange
1306
12-31
Common stock
6230 Stoneridge Mall Road, Pleasanton, California 94588
--
10x Genomics, Inc., was incorporated in Delaware on July 2, 2012. The Company started commercial and manufacturing operations and sales of its instruments and consumables in 2015. The company's integrated solutions include the company's Chromium instruments, its enzymes, reagents, microfluidic chips and other consumables, and software for analyzing biological systems.

Company Financials

EPS

TXG has released its 2024 Q4 earnings. EPS was reported at -0.40, versus the expected -0.11, missing expectations. The chart below visualizes how TXG has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TXG has released its 2024 Q4 earnings report, with revenue of 165.02M, reflecting a YoY change of -10.30%, and net profit of -49.03M, showing a YoY change of -0.16%. The Sankey diagram below clearly presents TXG’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime